Noradrenaline (norepinephrine) and depression: Role in aetiology and therapeutic implications

CNS Drugs

Volumn 12, Issue 4, 1999, Pages 293-305

  Van Moffaert, Myriam ^a,b   Dierick, Michel ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BRAIN MONOAMINE; MIRTAZAPINE; NEUROPEPTIDE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TYROSINE 3 MONOOXYGENASE; VENLAFAXINE;

AMNESIA; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOCUS CERULEUS; MONOAMINE METABOLISM; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; PSYCHOSOCIAL WITHDRAWAL; REVIEW; THYROID FUNCTION;

EID: 0032719985     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912040-00004     Document Type: Review

References (47)

1. Angst J. Epidemiology of depression. Psychopharmacology 1992; 106: 71-4
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-22
3. van Praag HM, Korf J. Endogenous depression with and without disturbances of 5-HT metabolism: a biochemical classification? Psychopharmacology 1971; 19: 148-52
4. Coppen A. Defects in monoamine metabolism and their possible importance in the pathogenesis of depressive syndromes. Psychiatr Neurol Neurochir 1969; 72 (2): 173-80
5. Stone TW. CNS neurotransmitters. In: Stone TW, editor. Neuropharmacology. New York (NY): WH Freedman and Company Limited. Spectrum, 1995: 44-64 (Biochemical & medicinal chemistry series)
6. Anand A, Charney DS. Catecholamines in depression. In: Honig A, Van Praag HM, editors. Depression: neurobiological, psychopathological and therapeutic advances. Chichester: John Wiley & Sons, 1997: 147-78
7. Brunello N, Racagni G. Rationale for the development of na reuptake inhibitors. Hum Psychopharmacol 1998; 13: S13-S19
8. Leonard BE. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 1997; 7 Suppl. 1: S11-S16
9. Leonard BE. Fundamentals of psychopharmacology. Chichester: John Wiley & Sons, 1997: 111-8
10. Checkley S. Biological models of depression and response in antidepressant treatments. In: Checkley S, editor. The management of depression. Oxford: Blackwell Science Ltd, 1998: 42-69
11. Cheetham SC, Katona CLE, Horton RW. Post-mortem studies of neurotransmitter biochemistry in depression and suicide. In: Horton R, Katona CLE, editors. London: Academic Press Ltd, 1991: 192-221
12. 2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986; 43: 954-9
13. Nutt DJ, Holman RB, Thomas DN. Noradrenergic mechanisms in anxiolytic and antidepressant drug action. In: Elliott JM, Healy DL, Marsden CA, editors, Experimental approaches to anxiety and depression. Chichester: John Wiley & Sons, 1992
14. Nelson JC. Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress Anxiety 1998; 7 Suppl. 10: 5-6
15. Baron BM, Ogden AM, Siegel BW, et al. Rapid downregulation of beta-adrenoreceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988; 154 (2): 125-34
16. Redmond AM, Leonard BE. An evaluation of the role of the noradrenergic system in the neurobiology of depression: a review. Hum Psychopharmacol 1997; 12 (5): 407-30
17. Kelly CK, Cooper SJ. Plasma noradrenaline response to electroconvulsive therapy in depressive illness. Br J Psychiatry 1997; 171: 182-6
18. Siever LJ, Coccano E, Davis KL. Hormone response to noradrenergic challenge. In: Halbreich U, Rose R, editors. Hormones in depression. New York (NY): Raven Press, 1986: 59-73
19. Brown SL, Steinberg RL, van Praag HM. The pathogenesis of depression: reconsideration of neurotransmitter data. In: den Boer JA, Sitsen JMA, editors. Handbook of depression and anxiety - a biological approach. New York (NY): Marcel Dekker, Inc., 1994: 317-47
20. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47: 411-8
21. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on anti-depressant induced remission of depression. Arch Gen Psychiatry 1996; 53: 117-28
22. Delgado PL, Price LH, Miller HL, et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression: Relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991; 27: 321-30
23. Delgado PL, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993, 29: 389-96
24. Montgomery SA. Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 1997; 7 Suppl. 1: S3-S9
25. Holm KJ, Spencer CM. Reboxetine. A review of its use in major depression. Drugs 1999; 12 (1): 65-83
26. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997; 11 (4) Suppl.: S9-S15
27. Burrows CD, Maguire KP, Noman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998; 58 Suppl. 14: 4-7
28. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998; 59 Suppl. 1: S20-39
29. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychopharm 1998 Feb; 13 Suppl. 1: S20-39
30. Berzewski H, Van Moffaert M, Cagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episode. Eur Neuropsychopharmacol 1997; 7 (1): 37-47
31. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997; 11: 33-7
32. Briley M. From dirty drugs to hyperselectivity and part way back again. Hum Psychopharmacol 1997; 12: 121-5
33. Holm KJ, Markham A. Mirtazapine. A review of its use in major depression. Drugs 1999; 57 (4): 607-31
34. Smith WT, Glaudin V, Panagides J. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 26: 191-6
35. Van Moffaert M, de Wilde J, Dierick M, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int J Clin Psychopharmacol 1995; 10: 3-9
36. Dierick M. A review of the efficacy and tolerability of venlafaxine. Eur Psychiatry 1997; 12 Suppl. 3: 15-25
37. Dierick M. An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 1996; 8 (3): 169-78
38. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49 (2): 282-94
39. Preskorn SH. Pharmacotherapeutic profile of venlafaxine. Eur Psychiatry 1997; 12 Suppl. 4: 285-94
40. Spencer CM, Wilde MI. Milnacipram. A review of its use in depression. Drugs 1998; 56 (3): 405-27
41. Schatzberg AF, Schildkraut JJ. Recent studies on norepinephline systems in mood disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press, 1995: 911-20
42. Healy D. The antidepressant era. Cambridge (MA): Harvard University Press, 1997
43. Van Moffaert M, Jannes C. An update of panic disorders, somatization, biological markers and outcome. Acta Psychiatrica Belg 1987; (3): 332-45
44. Weissman MM. Beyond symptoms: social functioning and the new antidepressants. J Pharmacol 1977; 11 (4): 5-8
45. Ansseau M, Bataille M, Van Moffaert M, et al. Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression. Hum Psychopharmacol 1996; 11; 293-8
46. Van Praag HM. Concerns about depression. Eur Psychiatry 1995; 10 (6): 269-76
47. Dierick M, Van Moffaert M. Depressieen serotonine. Belg Tijdschr Geneesk 1994; 50 (4): 293-8